SELNET: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Lati...
FUNDACAO ANTONIO PRUDENTE
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths....
2018-12-14 - 2023-12-31 | Financiado
2018-12-14 - 2023-12-31 | Financiado
VOGAS: Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach
FUNDACAO ANTONIO PRUDENTE
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening to...
2018-12-14 - 2022-09-30 | Financiado
2018-12-14 - 2022-09-30 | Financiado
CHIBCHA: Genetic study of Common Hereditary Bowel Cancers in Hispania and the Americas
FUNDACAO ANTONIO PRUDENTE
participó en un
FP7:
Colorectal cancer (CRC) is common in both sexes, has relatively poor outcome and has no major avoidable risk factor. Recent studies have sho...
Financiado
Financiado
* No se disponen de datos de la empresa actual.